HRMY News and Press, Harmony Biosciences Holdings Inc.

HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) PR ...

2024-06-24 10:56:01 ET More on Harmony Biosciences Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade) Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript Harmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call...

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY WAKIX is the first-and-only FDA-approved non-scheduled treatment option for excessive daytime sleepiness in pediatric patients 6 years of age and ol...

2024-06-21 16:15:08 ET Citigroup analyst issues UNDERPERFORM recommendation for HRMY on June 21, 2024 01:00PM ET. The previous analyst recommendation was Underperform. HRMY was trading at $29.96 at issue of the analyst recommendation. The overall analyst consensus : BUY....

2024-06-21 08:59:17 ET More on Harmony Biosciences Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade) Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript Harmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call...

2024-06-20 20:30:03 ET Citigroup analyst issues BUY recommendation for HRMY on June 20, 2024 07:09PM ET. HRMY was trading at $28.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold recomm...

2024-06-16 10:23:34 ET Summary This monthly article series provides a dashboard with aggregate industry metrics in healthcare. The healthcare sector is moderately overvalued relative to 11-year averages, and healthcare providers are the least overvalued subsector. Focus on IHF...

2024-06-05 08:50:35 ET More on Harmony Biosciences Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade) Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154...

HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1 Phase 2 signal detection study presented at the annual meeting of the Associated Professional Sleep Societies, "SLEEP 2024" PR Newswire...

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire PLYMOUTH MEETING, Pa. , May 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will pa...